Format

Send to

Choose Destination
Cancer Invest. 2011 Aug;29(7):451-5. doi: 10.3109/07357907.2011.590568. Epub 2011 Jun 22.

A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma.

Author information

1
Sarah Cannon Research Institute, Nashville, TN 37203, USA. jhainsworth@tnonc.com

Abstract

PURPOSE:

To evaluate the activity of panobinostat in refractory renal carcinoma.

PATIENTS AND METHODS:

Patients with advanced clear cell renal carcinoma who had received previous therapy with at least one angiogenesis inhibitor and one mTOR inhibitor were treated with panobinostat 45 mg orally twice a week, and were reevaluated after 8 weeks.

RESULTS:

Twenty patients were treated with no objective responses. All patients progressed or stopped treatment prior to the 16-week reevaluation. Panobinostat was generally well-tolerated.

CONCLUSION:

Panobinostat had no activity in this group of patients with refractory renal carcinoma. Further development of panobinostat in renal carcinoma is not recommended.

PMID:
21696296
DOI:
10.3109/07357907.2011.590568
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center